Lilly’s Omvoh Shows Four-Year Disease Clearance in Ulcerative Colitis

Long-term data from Eli Lilly and Company indicate that its interleukin (IL)-23p19 inhibitor mirikizumab-mrkz (brand name Omvoh) may provide sustained disease control in patients with moderately to severely active ulcerative colitis (UC), according to findings presented at Digestive Disease Week 2026.¹

The results, derived from the Phase 3 LUCENT clinical program, suggest that a proportion of patients who achieved disease clearance at one year were able to maintain that outcome through four years of continuous treatment, according to the trial investigators. Disease clearance is defined as the simultaneous achievement of symptomatic, endoscopic, and histologic remission—a composite endpoint considered more stringent than traditional clinical remission measures.²

Long-term durability observed in extension study

The LUCENT-3 open-label extension study followed patients who had previously responded to treatment in earlier trials. Among patients who achieved disease clearance at one year, 63.5% maintained that status at four years.³

In a more stringent assessment requiring endoscopic normalization in addition to symptomatic and histologic remission, 61.3% of patients maintained disease clearance through the same time period.¹ According to the company, this represents the first time an IL-23p19 inhibitor has demonstrated sustained disease clearance at four years in UC.¹

Although the analysis was not pre-specified, it provides insight into the durability of response across multiple disease domains, which has been an area of ongoing interest in inflammatory bowel disease research.¹

Raising the bar: what disease clearance means

Disease clearance as an endpoint reflects a shift toward more comprehensive treatment goals in UC. Unlike symptom-based endpoints alone, it integrates clinical symptoms with objective measures such as endoscopy and histology.¹

Previous real-world research has suggested that achieving disease clearance may be associated with reduced rates of hospitalization and surgical intervention, though these associations are not derived from the current study.¹

UC is a chronic inflammatory condition characterized by relapsing and remitting inflammation of the colon. The IL-23 pathway plays a central role in disease pathogenesis, and therapies targeting this pathway aim to reduce inflammatory signaling.³

Mechanism and regulatory background

Omvoh is a monoclonal antibody that selectively targets the p19 subunit of IL-23, thereby inhibiting the IL-23 signaling pathway.³ It was first approved in the US in 2023 for moderately to severely active UC and later expanded to include Crohn disease.⁴

Clinical development programs such as LUCENT (for UC) and VIVID (for Crohn disease) have evaluated its efficacy and safety across inflammatory bowel disease indications.⁴

Context within evolving treatment strategies

The emergence of IL-23 inhibitors reflects a broader trend in IBD treatment toward targeted biologic therapies. While earlier biologics focused on tumor necrosis factor inhibition, newer agents aim to more precisely modulate immune pathways implicated in disease progression.

Long-term data are particularly relevant in UC, where sustained remission remains a key treatment goal. Chronic disease burden, risk of complications, and the need for ongoing therapy underscore the importance of durability in treatment response.

However, the findings reported in the LUCENT-3 analysis should be interpreted within the context of an open-label extension study and a subset of patients who initially responded to therapy.¹ Additional peer-reviewed analyses and comparative studies may further clarify the role of Omvoh in long-term disease management.

References

1. Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years. (2026 May 5). PR Newswire. https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-is-the-first-and-only-il-23p19-to-demonstrate-durable-disease-clearance-in-ulcerative-colitis-through-four-years-302760458.html?utm_source=chatgpt.com
2. Sands, B. E., et al. (2024). Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases. https://doi.org/10.1093/ibd/izae024 
3. Brooks, A. (2026 May 5). Mirikizumab Maintains Disease Clearance in UC Through 4 Years in LUCENT-3 Extension. HCPLive. https://www.hcplive.com/view/mirikizumab-maintains-disease-clearance-in-uc-through-4-years-in-lucent-3-extens
4. Korta, A., Kula, J., & Gomułka, K. (2023 Jun 15). The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease. International journal of molecular sciences. https://doi.org/10.3390/ijms241210172